MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the first and only non-incisional permanent birth control method available, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to update the successful bilateral placement rate data on the Essure product labeling to 94.6%.
